...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of International Medical Research >Cholinesterase Inhibitors in the Clinical Management of Alzheimer's Disease: Importance of Early and Persistent Treatment
【24h】

Cholinesterase Inhibitors in the Clinical Management of Alzheimer's Disease: Importance of Early and Persistent Treatment

机译：胆碱酯酶抑制剂在阿尔茨海默氏病临床管理中的重要性：早期和持续治疗的重要性

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Alzheimer's disease is a neurodegenerative disease that greatly affects the quality of life of patients and their caregivers and places a heavy cost burden on the healthcare system. The cholinesterase inhibitors (ChEIs) donepezil, rivastigmine and galantamine have a central role in the treatment of Alzheimer's disease in the mild to moderate stages. Clinical trials with ChEIs have demonstrated therapeutic benefits for symptoms of cognition, function and behaviour across the disease course. These agents are most effective when started early in the disease course and used persistently, without treatment gaps. Early recognition of Alzheimer's disease and a global evaluation of treatment effectiveness are therefore essential. This article identifies barriers to early recognition and effective care of patients with Alzheimer's disease and discusses practical strategies to overcome them.
机译：阿尔茨海默氏病是一种神经退行性疾病，会极大地影响患者及其护理人员的生活质量，并给医疗系统带来沉重的成本负担。胆碱酯酶抑制剂（ChEIs）多奈哌齐，利凡斯的明和加兰他敏在轻度至中度阶段对阿尔茨海默氏病的治疗中具有重要作用。 ChEI的临床试验已证明在整个疾病过程中对于认知，功能和行为症状具有治疗益处。这些试剂在病程早期开始并持续使用而没有治疗差异时最有效。因此，早期识别阿尔茨海默氏病和全面评估治疗效果至关重要。本文确定了阿尔茨海默氏病患者早期识别和有效护理的障碍，并讨论了克服这些障碍的实用策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号